Corcept Therapeutics Inc. To Announce Second Quarter Financial Results And Corporate Update And Host Conference Call

MENLO PARK, CA--(Marketwired - July 29, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 5, 2015. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information

To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 40261436.

A replay will be available through August 19, 2015 at 1-888-843-7419 from the United States and 1-630-652-3042 internationally. The passcode is 40261436.

About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. Korlym® (mifepristone), a first generation competitive GR antagonist, is the company's first FDA-approved medication. The company is conducting a Phase 1/2 trial of mifepristone for the treatment of triple-negative breast cancer and is planning Phase 2 studies of CORT125134, one of its next-generation selective GR antagonists, for the treatment of Cushing's syndrome and an oncology indication. The company has developed a proprietary portfolio of other selective GR antagonists that competitively block the effects of cortisol but not progesterone. Corcept owns or has exclusively licensed extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic, oncologic and psychiatric disorders. It also holds composition of matter patents for its selective GR antagonists.